bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P3-12-20: The use of new delineation tool “MIRADA”, step-by-step development and first results of its use in early and locally advanced breast cancer patients
Authors: Xu H , Arsene Henry A , Robillard M , Amessis M , Kirova YM 
Published: May 2019

Abstract
Objectives: To describe the practical procedure of implementation and optimization of delineation using “Mirada” software, as well as evaluation of the automatic segmentation for the daily practice of lymph nodes (LN) and OARs (organs at risk) in early as well as locally advanced stage breast cancer patients.
Methods: Forty patients' CT scans in treatment position were selected and re-contoured according to the ESTRO guidelines. The atlas of dataset was then created for automatic delineation. Thirty patients with breast/chest wall and lymph nodes regions irradiated were recruited for evaluation. With the same treatment position, the CT scan images were acquired and then contoured by the MIRADA system automatically as well as by the radiation oncologist manually (as the reference). The Conformity Index (CI) was used to evaluate the concordance between both of them.
Results: The mean time for manual contour was 24.1±5.1 mins and 26.4±2.8 mins for the LN and the OARs resp. All the volumes of interest were contoured using the software (including corrections) in 30 minutes, which reduced the time of delineation of target volumes and OAR by about 40%. Of the 30 cases evaluated, the mean CI of 5 principal OARs showed ≥ 0.8. While the automatic contour of LN was less satisfactory with mean CI of 0.43±0.1 (0.23-0.52).
Conclusions: For the breast cancer patients, the studied software permitted to save time for delineation with acceptable OAR contours. The improvement of LN regions contour is needed. More cases and further evaluation are needed for the system to realize its routine use.
Citation Format: Xu H, Arsene Henry A, Robillard M, Amessis M, Kirova YM. The use of new delineation tool “MIRADA”, step-by-step development and first results of its use in early and locally advanced breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-20.
Abstract P3-16-01: Responding at patient's time of need: Scaling rapid access to evidence-based treatment plans
Authors: Ramarajan N , Srivastava R , Begum F , Gupta S , Pramesh C , Badwe R 
Published: May 2019

Abstract
Background: Cancer patients worldwide feel intense anxiety, often racing to start treatments at non expert centers. Further, imbalanced oncologist to patient ratios (˜1600: 1.8 M in India, ˜23,000: 15M in USA), impedes access to expertise. We study the impact of rapid evidence based expert treatment plans in relieving patient anxiety. Navya, a health services technology, generates personalized treatment plans that maps within NCCN Resource Stratified Guidelines [SABCS 2017]. This is vetted on mobile by oncologists at tertiary centers like TMC NCG to provide expert opinion reports to patients. Since 2015, ˜19,457 patients from 57 countries have reached out for an online opinion. On the ground, 78% of patients received evidence based treatments recommended by Navya [ASCO 2017].
Methods: To assess impact of timeliness, a prospective series of patients (from Sep '17 to April '18) were asked: “Were you relieved to receive expert opinion report in [x] days?” “Does it matter to you to receive expert opinion report in 1 day?” To assess time savings, preliminary reports with treatment options from NCCN and TMC NCG guidelines were shared with patients who matched all guidelines criteria. Subsequently, expert opinion reports were shared as usual.
Results: 543/701 patients responded to phone follow-up. 97% [± 3.2] were relieved to receive expert opinion reports in 1-2 days (103/106) vs 83% [± 3.8 ] for 3+ days (365/437). Of those not relieved by 3+ day turnaround, 83% stated that it would matter to receive expert opinion reports in 1 day (60/72). The first 300 preliminary reports shared in median time of 3.37 hours, resulted in 90% time savings vs expert opinion reports. On 10% of the preliminary reports, experts added information such as de-/escalating therapy (18/31), and additional diagnostic tests (6/31).
Conclusions: Navya relieves patient anxieties by responding at the time of need with evidence based treatment plans. Scaling such health services technologies to patients worldwide is feasible.
Citation Format: Ramarajan N, Srivastava R, Begum F, Gupta S, Pramesh C, Badwe R. Responding at patient's time of need: Scaling rapid access to evidence-based treatment plans [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-16-01.
Abstract P4-02-15: The effect of the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines in HER2 positivity rates among women with breast cancer in SEER registries
Authors: Wang XK , Hu N , Herget K , Cinbis BR , Gulbahce EH 
Published: May 2019

Abstract
Introduction: The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) revised the HER2 testing guidelines in breast cancer (BC) which was published in December 2013, practically becoming effective in 2014. Since then, many studies reported a significant increase in HER2 positivity rate in BC. Although HER2 has been routinely evaluated in BC for over a decade, HER2 status was not included in SEER registries until 2010. The aim of this study is to look at the effect of the 2013 ASCO/CAP guidelines on HER2 status in the SEER database that captures approximately 28% of all cancers in the US.
Material and Methods. Using data from 18 SEER cancer registries between the years of 2010-2015 when HER2 status for breast cancers was available, women with invasive BC were identified and their HER2 status and race was recorded. The Chi-square test was used to test the significance between positive proportions before and after the new ASCO/CAP guidelines were effective. Logistic regression was used to test if the changes in positivity rate were the same among different races. All calculations were made after excluding cases with unknown/missing HER2 status.
Results: We identified 376,278 women diagnosed with invasive BC between the years 2010-2015. HER2 positivity before 2014 (2010-2013) was 14.4% compared to 15.6% after 2013 (2014-2015) (p&lt;0.001). HER2 positivity increased in all races after 2013. There was no significant difference in the increase of HER2 positivity between whites and blacks after the new guidelines went into effect. Unknown/missing HER2 status continually decreased over the study period from 7.4% in 2010 to 5.3% in 2015. Overall unknown/missing HER2 was significantly different among races: 6.5% in whites; 7.1% in blacks; and 6.2% in other races (p&lt;0.01).
Conclusion: Revised ASCO/CAP HER2 guidelines significantly increased HER2 positivity rates in SEER registries from 14.4% to 15.6% after implementation started in 2014. HER2 positivity increased in all races after 2013. Unknown/missing HER2 status is significantly different among different races. Blacks have highest unknown/ missing HER2 status in SEER registries.
Citation Format: Wang XK, Hu N, Herget K, Cinbis BR, Gulbahce EH. The effect of the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines in HER2 positivity rates among women with breast cancer in SEER registries [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-02-15.
Abstract P4-06-09: Withdrawn
Authors: Corsi F , Andreata F , Truffi M , Sorrentino L , D'Addio F , Monieri M , Gambaro A , Bellini M , Prosperi D , Mazzucchelli S 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Corsi F, Andreata F, Truffi M, Sorrentino L, D'Addio F, Monieri M, Gambaro A, Bellini M, Prosperi D, Mazzucchelli S. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-09.
Abstract P4-06-20: Delivering tumour antigens survivin and mucin-1 on virus-like particles for breast cancer immunotherapy
Authors: Kramer K , Braeden D , Young VL , Walker GF , Ward VK , Young SL 
Published: May 2019

Abstract
Breast cancer is the most frequently diagnosed cancer in women worldwide. Although there are a variety of treatment options available, breast cancer is a difficult disease to treat and many patients experience recurrence following treatment. We have previously shown that tumour antigens delivered on virus-like particles (VLP) induce a targeted anti-cancer immune response. In this study we investigated whether combining the two tumour antigens survivin and mucin 1 as vaccine targets can induce a superior anti-cancer immune response for breast cancer immunotherapy. VLP were designed to recombinantly express the murine survivin epitope. Following expression of Survivin-VLP, aberrantly glycosylated mucin 1 (MUC1) peptide was conjugated onto the Survivin-VLP using intracellular cleavable bis-arylhydrazone linking strategy. Western Blot analysis and electron microscopy confirmed Survivin-VLP expression and UV absorption confirmed conjugation of the MUC1 peptide to the Survivin-VLP. C57mg.MUC1 breast cancer cells were injected into the mammary fat pad of C57Bl/6 and MUC1 transgenic mice. Once tumours were palpable, mice were vaccinated with the Survivin-MUC1-VLP and controls of DPBS, VLP without antigen or VLP delivering either survivin or MUC1 antigen. Tumour growth and mouse survival were monitored for 80 days. Mice vaccinated with Survivin-MU1-VLP delivering both antigens showed enhanced survival (D78) compared to mice vaccinated with VLP delivering only one of the antigens (D66) and controls (D53). Delivery of two tumour antigens induced an enhanced anti-tumour immune response compared to delivery of single tumour antigens. The induction of multiple immune responses against different tumour antigens may apply additional evolutionary pressure upon tumours, prolonging the ability for tumours to develop resistance, or escape through the proliferation of a resistant subpopulation. The use of VLP for the delivery of multiple antigens and adjuvants represents a promising approach to improve cancer immunotherapy for breast cancer.
Citation Format: Kramer K, Braeden D, Young VL, Walker GF, Ward VK, Young SL. Delivering tumour antigens survivin and mucin-1 on virus-like particles for breast cancer immunotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-20.
Abstract P4-07-02: Withdrawn
Authors: Katzenellenbogen BS , Guillen VS , Ziegler Y , Kim SH , Laws MJ , Zhao Y , Yasuda MA , Li Z , El-Ashry D , Katzenellenbogen JA 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Katzenellenbogen BS, Guillen VS, Ziegler Y, Kim SH, Laws MJ, Zhao Y, Yasuda MA, Li Z, El-Ashry D, Katzenellenbogen JA. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-07-02.
Abstract P4-08-22: Impact of application of AJCC 8th edition on survival rate of the breast cancer
Authors: Kwon S , Yoon DS , Bae IE , Choi WJ , Choi IS , Lee SE , Moon JI , Sung NS , Park SM 
Published: May 2019

Abstract
Background
The AJCC 8 edition has changed much in comparison with the 7 edition. In addition to TNM stage, biologic marker (ER, PR, HER2), Histologic grade and multigene assays (oncotype Dx.) should be considered for staging. and it has been applied since January 1, 2018.
patients were recategorized and analyzed in order to know if this more complex classification helps to predict the real prognosis of the patients,
Method
We review patients who were diagnosed and treated as breast cancer at Konyang Universty Hospital. we studied retrospectively 582 patients who were followed up and were able to review.
Stage was classified according to AJCC 7th edition and AJCC 8th edition. survival rate of each stage were analyzed in both editions.
Result
Mean follow up period was 68.6 months. Total 582 patients were included. There was no change in the stage in 257 patients. In 195 patients, the stage was elevated and in 130 patients, the stage was changed down. When classified as AJCC 7th edition, the 5year-survival rate was 95.9% in stage I, 97.9% in stage II, 93.1% in stage III and 89.9% in stage IV. The survival rate of patients in stage I was lower than that of stage II. However, when the AJCC 8th edition was applied, the 5- year survival rate was 97.9% in stage I, 96.9% in stage II, 92.2% in stage III, and 89.9% in stage IV. In 8th edition, the patients in lower stage has higher survival rate.
Conclusion
The prediction of survival rate by stage was more accurate and the difference in survival rate of each stages was more clearly distinguished when The AJCC 8th edition was applied than AJCC 7th edition. AJCC 8th edition was reliable and useful for prediction of prognosis of breast cancer patient.
Citation Format: Kwon S, Yoon DS, Bae IE, Choi WJ, Choi IS, Lee SE, Moon JI, Sung NS, Park SM. Impact of application of AJCC 8th edition on survival rate of the breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-22.
Abstract P4-08-28: Clinical risk prediction models for breast cancer: A review of models developed between 2010 and 2018
Authors: Siesling S , Hueting T , Tip B , Mentink R , Koffijberg E 
Published: May 2019

Abstract
Background:
Clinical prediction models provide insight in the probability of a specified event happening based on the personal characteristics of the patient. Predicted probabilities support physicians in tailoring clinical decisions to the patients needs. Throughout the past decades, the amount of developed prediction models has grown, yet the application of these models in daily medical practice falls behind. It is currently uncertain how many prediction models exist to support decision making in breast cancer care and exactly which decisions may be supported using prediction models. This study aimed to identify all developed prediction models on breast cancer care and to assess the clinical applicability of the models in the target breast cancer population.
Methods:
A literature search was performed to identify developed risk prediction models published from January 2010 up to June 2018. Models predicting breast cancer related events were included. Identified models were assessed on the reported transparency and reproducibility and incorporated in the online platform for prediction models: Evidencio. Clinical applicability of the models was assessed using a digital implementation of the Dutch breast cancer guideline called Oncoguide. Models were assigned to location in the guideline where they may support clinical decisions.
Results:
A total of 91 studies describing the development of 142 prediction models were identified. Thorough assessment showed that 31 models were reported in full having the description of all the necessary parameters to reproduce the underlying statistical formula and were incorporated in Evidencio.com. For 95 models the formula could be derived through the presented nomogram, table, or online calculator. The remaining 16 models were lacking information to construct any method to predict the outcome of an individual patient and could therefore not be used in practice.
Conclusion:
A total of 142 prediction models were developed between January 2010 and June 2018. The overall quality of reporting was poor as 111 models were not described transparently. All identified models were assigned to the location in the guideline of which the model may support clinical decision making. Further assessment is necessary on the clinical impact and validity of the models in the Dutch population before implementing them in the guideline.
Citation Format: Siesling S, Hueting T, Tip B, Mentink R, Koffijberg E. Clinical risk prediction models for breast cancer: A review of models developed between 2010 and 2018 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-28.
Abstract P4-08-33: The significance of Oncotype DX recurrence score in T1-2N1M0 ER positive HER2 negative breast cancer: An analysis combined with the prognostic stage in the updated AJCC 8th edition
Authors: Chen H , Wang M , Zhang P , Zhang M , Wu K 
Published: May 2019

Abstract
Purpose: Oncotype DX recurrence score (Oncotype DX RS) is applied in the prognostic stage in T1-2N0M0 ER+/HER2- breast cancer. But its significance is unclear in cases with T1-2N1M0 ER+/HER2- disease. Our study was to evaluate the prognostic significance of Oncotype DX RS in combination with the prognostic stage in the updated AJCC 8th edition. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was searched to identify invasive ductal breast cancer cases in T1-2N1M0 stage with ER positive HER2 negative status and Oncotype DX RS diagnosed between 2004 and 2012. Patients with unknown histologic grade or PR status, no or unknown surgery performed, or less than 6 months of follow up were excluded. Patients with RS 0-10, 11-25, &gt;25 were categorized into low risk, midrange risk and high risk groups respectively. Comparisons of the distribution of RS groups among prognostic stages were performed using Pearson's chi-square. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared across RS groups using the log-rank statistic. Cox models were fitted to compare the association between RS groups, prognostic stages and BCSS or OS after adjusting for other characteristics. Results: Altogether 4059 cases were enrolled, which were categorized into prognostic stage IA-IIIA (only 357 cases in stage IIB and 35 cases in stage IIIA). More than 60% cases in prognostic stage IA-IIA had their RS in midrange risk group. There were decreasing proportion of low risk RS group and increasing proportion of high risk RS group with the ascending of prognostic stages (P&lt;0.001). The median follow up was 59 months. There were significant differences in BCSS and OS among RS groups (log-rank P&lt;0.001). In the subgroup analysis, there were also significant differences in BCSS and OS among RS groups in prognostic stages IA-IIA. In the multivariate Cox analysis, the RS group was an independent prognostic factor for BCSS (midrange risk vs. low risk, HR=3.647, 95% CI: 1.124-11.837, P=0.031; high risk vs. low risk, HR=15.372, 95% CI: 4.600-51.374, P&lt;0.001) and OS (midrange risk vs. low risk, HR=1.718, 95% CI: 1.039-2.840, P=0.035; high risk vs. low risk, HR=4.225, 95% CI: 2.462-7.251, P&lt;0.001) along with the prognostic stage. Conclusions: Oncotype DX RS has prognostic significance in T1-2N1M0 ER+/HER2- disease. Further prospective research is warranted.
Citation Format: Chen H, Wang M, Zhang P, Zhang M, Wu K. The significance of Oncotype DX recurrence score in T1-2N1M0 ER positive HER2 negative breast cancer: An analysis combined with the prognostic stage in the updated AJCC 8th edition [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-33.
Abstract P4-10-04: Assessment of clinical trial participation on breast cancer survival
Authors: Parise C , Caggiano V 
Published: May 2019

Abstract
Background
Accredited cancer treatment centers offer clinical trials for patients since it is universally accepted that participation in these trials is advantageous.
Purpose
The purpose of this study was to assess whether clinical trial participation was associated with a survival advantage.
Methods
We identified 308,291 cases of first primary female invasive breast cancer from the California Cancer Registry 2000-2015. Participation in a clinical trial was documented. Clinical trials were defined as National Cancer Institute (NCI) sponsored studies such as National Surgical Adjuvant Breast and Bowel Project (NSABP) and Southwest Oncology Group (SWOG); pharmaceutical trials; and local investigator initiated studies.
The distribution of age, race/ethnicity, socioeconomic status (SES), and stage between clinical trial participants and non-participants was compared using contingency tables and the χ2 Test.
Kaplan-Meier Survival Analysis and the Log Rank test were used to compare differences in breast cancer specific survival between participants and non-participants. Cox Regression Analysis was used to estimate the risk of mortality between participants and non-participants after adjusting for age, race/ethnicity, SES, grade, and treatment. Analyses were conducted separately for each stage. Hazard ratios (HR) and 95% confidence intervals (CIs) were reported.
Results
There were 3,517 (1.1%) patients who participated in a clinical trial. Almost 50% of participants were enrolled in an NCI trial, 38% in a local/investigator initiated study, and 13% were in a trial sponsored by a pharmaceutical company. Trial participation was highest for patients less than 45 years of age (21.9%) and lowest in patients 70 years of age and older (12.3%). Most participants were in stage 2 (44.6%). Participation increased with increasing SES. Only 8.5% of participants were in the lowest SES whereas 35.4% were in the highest SES.
Unadjusted survival analysis indicated that there was no survival advantage for stage 1 patients (χ2 = 0.41, p=0.52) whereas study participants in stages 2, 3, and 4 had statistically significantly better survival. Adjusted hazard ratios indicated that stage 2 patients participating in a trial had a 23% reduced risk of mortality (HR=0.77; CI: 0.65 - 0.94). For patients in stage 4, the risk of mortality was reduced by 36% (HR=0.64; CI: 0.47 - 0.87). There was no risk reduction for patients in stages 1 and 3.
Conclusion
Only a small percent of patients enroll in breast cancer clinical trials and participation is correlated with age and SES. There is a survival advantage for participation in a clinical trial for stages 2 and 4 patients.
Citation Format: Parise C, Caggiano V. Assessment of clinical trial participation on breast cancer survival [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-10-04.